PMID- 30460863
OWN - NLM
STAT- MEDLINE
DCOM- 20190104
LR  - 20190104
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 56
IP  - 1
DP  - 2018 Dec
TI  - Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes 
      mellitus.
PG  - 567-572
LID - 10.1080/13880209.2018.1504972 [doi]
AB  - CONTEXT: TangGanJian (TGJ) has a curative effect in the clinical treatment of 
      nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), 
      while the mechanism involved in the treatment process remains unclear. OBJECTIVE: 
      This study details the mechanism of TGJ on the treatment of NAFLD with T2DM. 
      MATERIALS AND METHODS: NAFLD was induced in T2DM rat model. Male Wistar rats were 
      assigned into six groups: Group I (control), Group II (model), Group III 
      (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V 
      (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All 
      rats in each group were treated with the corresponding drugs by gavage for 
      8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of 
      inflammatory and oxidative stress were analysed utilizing one-way ANOVA. RESULTS: 
      The contents of TNF-alpha (15.794 +/- 3.302 pg/mL), IL-6 (76.801 +/- 8.491 pg/mL), IL-1beta 
      (100.101 +/- 13.150 pg/mL), CRP (1.052 +/- 0.079 pg/mL) and MDA (3.972 +/- 0.159 pg/mL) 
      were obviously elevated in NAFLD with T2DM rats compared to controls. Except for 
      the IL-6, the levels of other markers declined in a dose-dependent manner after 
      treatment with TGJ. The SOD (14.139 +/- 1.479 U/mgprot) and GSH-PX 
      (81.511 +/- 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, 
      while the levels of these indicators increased after treatment with TGJ. 
      CONCLUSIONS: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the 
      inflammatory response and the oxidative stress capacity.
FAU - Fan, Yanbo
AU  - Fan Y
AD  - a Science and Education Department , Wuhan Hospital of Traditional Chinese 
      Medicine , Wuhan , PR China.
AD  - b Post-Doctoral Research Center of Mayinglong Pharmaceutical Group Co., Ltd. , 
      Wuhan , PR China.
FAU - Xiong, Wei
AU  - Xiong W
AD  - c Vascular Surgery , Wuhan No. 1 Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST) , Wuhan , PR China.
FAU - Li, Jingjing
AU  - Li J
AD  - d College of Basic Medicine , Hubei University of Chinese Medicine , Wuhan , PR 
      China.
FAU - Hu, Aimin
AU  - Hu A
AD  - e Endocrinology Department , Wuhan Hospital of Traditional Chinese Medicine , 
      Wuhan , PR China.
FAU - He, Zhiwei
AU  - He Z
AD  - f Department of Pharmacy , Xiangyang Hospital of Traditional Chinese Medicine , 
      Xiangyang , Hubei, PR China.
FAU - Zhang, Jiawen
AU  - Zhang J
AD  - f Department of Pharmacy , Xiangyang Hospital of Traditional Chinese Medicine , 
      Xiangyang , Hubei, PR China.
FAU - Zhou, Guoyun
AU  - Zhou G
AD  - g Department of Pharmacy , Wuhan Hospital of Traditional Chinese Medicine , Wuhan 
      , PR China.
FAU - Yin, Qiang
AU  - Yin Q
AD  - h Department of Management , Xinjiang Uygur Pharmaceutical Co., Ltd. , Wulumuqi , 
      PR China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (IL6 protein, human)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Experimental/chemically induced/complications/*drug 
      therapy/metabolism
MH  - Diabetes Mellitus, Type 2/chemically induced/complications/*drug 
      therapy/metabolism
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Insulin/blood
MH  - Interleukin-1beta
MH  - Interleukin-6/blood
MH  - Liver/drug effects
MH  - Male
MH  - Non-alcoholic Fatty Liver Disease/complications/*drug therapy/metabolism
MH  - Oxidative Stress/drug effects
MH  - Pioglitazone/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC6249541
OTO - NOTNLM
OT  - GSH-PX
OT  - SOD
OT  - TNF-alpha
OT  - Therapy
OT  - inflammation
OT  - oxidative stress
EDAT- 2018/11/22 06:00
MHDA- 2019/01/05 06:00
PMCR- 2018/11/21
CRDT- 2018/11/22 06:00
PHST- 2018/11/22 06:00 [entrez]
PHST- 2018/11/22 06:00 [pubmed]
PHST- 2019/01/05 06:00 [medline]
PHST- 2018/11/21 00:00 [pmc-release]
AID - 1504972 [pii]
AID - 10.1080/13880209.2018.1504972 [doi]
PST - ppublish
SO  - Pharm Biol. 2018 Dec;56(1):567-572. doi: 10.1080/13880209.2018.1504972.